- Home
- CPBI vs ATNM Comparison
CPBI vs ATNM Comparison
Compare CPBI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | ATNM |
|---|---|---|
| Founded | 2023 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 36.8M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CPBI | ATNM |
|---|---|---|
| Price | $17.57 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.6K | ★ 104.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $1.02 |
| 52 Week High | $17.87 | $1.95 |
Technical Indicators
Market Signals| Indicator | CPBI | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 43.37 |
| Support Level | $17.37 | $1.02 |
| Resistance Level | $17.87 | $1.25 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 61.33 | 38.74 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.